OCT in Rare Chorioretinal Diseases

Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.

The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.

Study Overview

• Status: Recruiting
• Conditions: Polypoidal Choroidal Vasculopathy; Central Serous Chorioretinopathy; Retinal Artery Occlusions; Retinal Arterial Macroaneurysm; Juxtafoveal Telangiecasia

Detailed Description

Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time by measuring the intensity of reflected light. Tomographic images are generated by scanning the optical probe beam across the tissue structure of interest. OCT has become one of the most widely used imaging technologies by ophthalmologists. Its advantages include being a non-contact imaging modality, having micron-level resolution, producing a digital image that can be viewed electronically, and providing a reproducible quantitative measurement. New functional OCT including Doppler OCT and OCT angiography may allow an assessment of retinal blood flow and do away with the need for the more invasive fluorescein angiography (FA) test.

Thus, if the diagnostic data provided by functional OCT are at least equivalent or superior to those achieved by FA, patients and healthcare providers could realize a substantial benefit in utilizing this technology in the evaluation of retinal vascular disease. Even in the scenario in which an FA is not usually clinically indicated, OCT angiography may provide information over that of standard OCT and clinical examination and history, that might help clinicians better understand the etiology of the disease, and may even help inform treatment response.

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

• Study Contact: Name: Kevin Lathrop; Phone Number: 503-494-8024; Email: lathropk@ohsu.edu
• Study Contact Backup: Name: Denny Romfh, OD; Phone Number: 503-494-4351; Email: romfhd@ohsu.edu

Study Locations

• United States
  • Oregon
    • Portland, Oregon, United States, 97239-3098
      • Recruiting
      • Casey Eye Institute, Oregon Health & Science University
      • Contact: Kevin Lathrop; Phone Number: 503-494-8024; Email: lathropk@ohsu.edu
      • Sub-Investigator: John Campbell, MD, MPH
      • Sub-Investigator: Andreas Lauer, MD
      • Sub-Investigator: Christina Flaxel, MD
      • Sub-Investigator: Michael Klein, MD
      • Sub-Investigator: Steven Bailey, MD
      • Contact: Denny Romfh, OD; Phone Number: 503-494-4351; Email: romfhd@ohsu.edu
      • Sub-Investigator: Eric Suhler, MD
      • Sub-Investigator: David Huang, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 100 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Individuals 18 years of age and older presenting to the Retina Service within the Department of Ophthalmology at the Casey Eye Institute of Oregon Health & Science University with signs and symptoms of rare choroidal or retinal diseases will be evaluated for enrollment into this study.

Description

Subject-Level Criteria:

Inclusion a. Diagnosis of retinal or choroidal disease

Exclusion

1. Inability to give informed consent.
2. Inability to complete study tests within a 30 day period
3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant.
4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
5. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.

Study-Eye Criteria:

Inclusion

a. Diagnosis of retinal or choroidal disease

Exclusion

1. Inability to maintain stable fixation for OCT imaging.
2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)
3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal).
4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Rare Chorioretinal Disease; Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Retinal and Choroidal Blood Flow	Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min.	One year

Collaborators and Investigators

• Sponsor: Oregon Health and Science University
• Investigators: Principal Investigator: Thomas Hwang, MD, Oregon Health & Science Univeristy

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2014
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: May 15, 2014
• First Submitted That Met QC Criteria: May 16, 2014
• First Posted (Estimated): May 19, 2014

Study Record Updates

• Last Update Posted (Actual): February 12, 2024
• Last Update Submitted That Met QC Criteria: February 8, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Imaging; Retina; Optical coherence tomography
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Arterial Occlusive Diseases; Eye Diseases; Retinal Diseases; Uveal Diseases; Choroid Diseases; Metaplasia; Hypertension; Aneurysm; Hypertensive Retinopathy; Neovascularization, Pathologic; Choroidal Neovascularization; Central Serous Chorioretinopathy; Retinal Artery Occlusion; Retinal Arterial Macroaneurysm; Polypoidal Choroidal Vasculopathy
• Other Study ID Numbers: IRB00010511